1. SAT0155 Adalimumab in combination with non-methotrexate conventional synthetic disease modifying rheumatic drugs in a clinical trial setting. (15th June 2017) Authors: Keystone, EC; Suboticki, J; Griffith, J; Zhang, Y; Kremer, JM Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 828 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0047 Predicting maintenance of response based on disease characteristics and early clinical response in rheumatoid arthritis patients upon withdrawal of adalimumab. (15th June 2017) Authors: Smolen, JS; Emery, P; Zhang, H; Wang, X; Suboticki, J; Sainsbury, I; Kavanaugh, A Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 785 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0083 The relevance of elevated crp as an inclusion criterion in clinical trials in patients with rheumatoid arthritis. (15th June 2017) Authors: Scoville, C; Suboticki, J; Zhong, S; Keystone, E Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗